BÖLÜM 7

PARKİNSON HASTALIĞI: KÖKLERİNDEN GENETİĞİNE

İlayda ŞİŞLİ[1]
Hilal KOYUNCU[2]
Tuğba KESKİN[3]
Şengül TURAL[4]

GİRİŞ

Parkinson hastalığı (PD), dopaminerjik nöron kaybı ile karakterize edilen ilerleyici bir nörodejeneratif bozukluktur. Bu bölümde, Parkinson hastalığının genetik ve çevresel temelleri detaylı bir şekilde incelenmiştir. PD'nin genetik temellerinde, *PARK* genlerindeki mutasyonların hastalığın gelişiminde önemli rol oynadığı bulunmuştur. Ayrıca, çevresel faktörlerin PD üzerindeki etkisi, pestisitler, endüstriyel toksinler ve diğer çevresel etmenlerle maruziyetin hastalığın riskini artırabileceği vurgulanmıştır. Ek olarak, genetik ve çevresel faktörlerin birleşerek Parkinson hastalığının ortaya çıkmasına neden olduğu ve bu etkileşimin hastalığın gelişiminde kritik bir rol oynadığı tartışılmıştır. Ayrıca, Parkinson hastalığının patogenezinde genetik yatkınlık ve çevresel faktörlerin nasıl bir araya geldiği, mitokondriyal disfonksiyon, oksidatif stres ve α-sinüklein birikimi gibi patolojik süreçlerle ilişkilendirilmiştir. Araştırmalara göre Parkinson hastalığının tedavisinde kullanılan semptomatik yaklaşımlar ve genetik testler, hastalığın erken teşhisi ve tedavi sürecinde önemli bir yer tutmaktadır. Bunun yanı sıra, gelecekteki tedavi yöntemlerinin genetik ve çevresel etkileşimlere dayalı kişiselleştirilmiş tedavi stratejileri geliştirilmesi gerektiği vurgulanmıştır.

[1] Yüksek Lisans Öğrencisi, Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji AD., ilaydasisli@outlook.com, ORCID iD: 0009-0009-8918-7839
[2] Arş. Gör. Dr., Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji AD., hilal.koyuncu@omu.edu.tr, ORCID iD: 0000-0002-9903-1514
[3] Dr., Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji AD., tugba.keskin@omu.edu.tr, ORCID iD: 0000-0002-7071-1444
[4] Prof. Dr., Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji AD., stural@omu.edu.tr, ORCID iD: 0000-0002-8946-8165

DOI: 10.37609/akya.3862.c1432

hastalığın ilerlemesini durdurmada veya tersine çevirmede yeterince etkili değildir. Levodopa gibi dopaminerjik tedaviler, motor semptomları hafifletmede etkili olsalar da, uzun vadede diskineziler ve motor dalgalanmalar gibi yan etkilerle sınırlıdır. Son yıllarda gelişen genetik tedavi yaklaşımları, Parkinson hastalığına yönelik umut verici çözümler sunmaktadır. Dopamin üretimini destekleyen gen terapileri, nörotrofik faktörlerin (*GDNF*, *BDNF* gibi) kullanımı ve CRISPR/Cas9 tabanlı gen düzenleme teknolojileri, hastalığın patolojik mekanizmalarını hedef alarak daha etkili ve köklü tedavi imkanları sağlayabilir. Özellikle, α-sinüklein birikiminin azaltılmasına yönelik terapiler ve mitokondriyal fonksiyonları iyileştirmeye odaklanan yaklaşımlar, hastalık ilerleyişini yavaşlatma potansiyeline sahiptir. Ancak, bu teknolojilerin klinik kullanıma girmesi için daha fazla araştırma ve etik değerlendirme gerekmektedir. Sonuç olarak, Parkinson hastalığı tedavisinde genetik ve çevresel etkileşimleri temel alan kişiselleştirilmiş tedavi stratejilerinin geliştirilmesi çok büyük bir potansiyel taşımaktadır. Bu yönde atılacak adımlar, hem hastalığın erken dönemlerinde etkili müdahalelere olanak sağlayacak hem de ilerleyen dönemlerde semptomları daha iyi yönetmek için yeni yollar açacaktır. Gelecekte, genetik teknolojilerin kullanımındaki ilerlemeler ve çevresel risk faktörlerinin daha iyi anlaşılması, Parkinson hastalığıyla mücadelede yeni ufuklar açabilecektir.

KAYNAKLAR

1. Parkinson J. An essay on the shaking palsy. *The Journal of neuropsychiatry and clinical neurosciences*. 2002;14(2):223–36
2. Lees AJ. Unresolved issues relating to the shaking palsy on the celebration of James Parkinson's 250th birthday. *Movement disorders: official journal of the Movement Disorder Society*. 2007;22(S17):S327–S34
3. Deng H, Gao K, Jankovic J. The VPS35 gene and Parkinson's disease. *Movement Disorders*. 2013;28(5):569–75
4. Jankovic J. Parkinson's disease: clinical features and diagnosis. *Journal of neurology, neurosurgery & psychiatry*. 2008;79(4):368–76
5. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. *Nature reviews Disease primers*. 2017;3(1):1–21
6. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. *Neurologic clinics*. 2005;14(2):317
7. De Virgilio A, Greco A, Fabbrini G, et al. Parkinson's disease: autoimmunity and neuroinflammation. *Autoimmunity reviews*. 2016;15(10):1005–11
8. Kasten M, Chade A, Tanner CM. Epidemiology of Parkinson's disease. *Handbook of clinical neurology*. 2007;83:129–51
9. Lesage S, Brice A. Role of Mendelian genes in "sporadic" Parkinson's disease. *Parkinsonism & related disorders*. 2012;18:S66–S70
10. Spinazzi M, Casarin A, Pertegato V, et al. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. *Nature protocols*. 2012;7(6):1235–46
11. Thyagarajan D, Bressman S, Bruno C, et al. A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. *Annals of neurology*. 2000;48(5):730–6

12. Moon HE, Paek SH. Mitochondrial dysfunction in Parkinson's disease. *Experimental neurobiology*. 2015;24(2):103
13. Kolata G. Monkey Model of Parkinson's Disease: A contaminant of illicit drugs has caused Parkinson's disease in humans and monkeys. *Science*. 1983;220(4598):705–
14. Dickson DW. Parkinson's disease and parkinsonism: neuropathology. *Cold Spring Harbor perspectives in medicine*. 2012;2(8):a009258
15. Dölle C, Flønes I, Nido GS, et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. *Nature communications*. 2016;7(1):13548
16. Cadet JL, Brannock C. Invited review free radicals and the pathobiology of brain dopamine systems. *Neurochemistry international*. 1998;32(2):117–31
17. Wang B, Abraham N, Gao G, et al. Dysregulation of autophagy and mitochondrial function in Parkinson's disease. *Translational Neurodegeneration*. 2016;5:1–9
18. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. *Neurology*. 1993;43(6):1173–
19. Adam-Vizi V, Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. *Trends in pharmacological sciences*. 2006;27(12):639–45
20. Halliwell B, Gutteridge JM. Free radicals in biology and medicine: Oxford university press, USA; 2015.
21. Burchell VS, Nelson DE, Sanchez-Martinez A, et al. The Parkinson's disease–linked proteins Fbxo7 and Parkin interact to mediate mitophagy. *Nature neuroscience*. 2013;16(9):1257–65
22. Akbayır E, Şen M, Ay U, et al. Parkinson hastalığının etyopatogenezi. *Deneysel Tıp Araştırma Enstitüsü Dergisi*. 2017;7(13):1–23
23. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. *Neurology*. 2000;55(9):1358–63
24. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2007;78(8):819–24
25. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. *Brain research*. 1997;767(2):340–4
26. Gao X, Dluzen D. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. *Neuroscience*. 2001;103(2):385–94
27. Gajjar T, Anderson L, Dluzen D. Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. *Journal of neural transmission*. 2003;110:1215–24
28. Datla KP, Murray HE, Pillai AV, et al. Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. *Neuroreport*. 2003;14(1):47–50
29. Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. *Science*. 1983;219(4587):979–80
30. Tipton K, McCrodden J, Sullivan J. Metabolic aspects of the behavior of MPTP and some analogues. *Advances in neurology*. 1993;60:186–93
31. Spivey A. Rotenone and paraquat linked to Parkinson's disease: human exposure study supports years of animal studies. National Institute of Environmental Health Sciences; 2011.
32. Minbay Z, Gören B, Eyigör Ö. 6-OHDA ile Oluşturulan Parkinson Hastalığı Modelinde Astrogliozis ve Glutamat Taşıyıcı Protein GLT1 Ekspresyonu. *Uludağ Üniversitesi Tıp Fakültesi Dergisi*. 2020;46(3):385–94
33. Oto G, Önay E. Çevresel Toksinler ve Parkinson Hastalığı. *Turkiye Klinikleri Pharmacology-Special Topics*. 2022;10(1):59–65
34. Granado N, Ares-Santos S, Moratalla R. Methamphetamine and Parkinson- s Disease. *Parkinson's disease*. 2013;2013(1):308052
35. Sherer TB, Betarbet R, Testa CM, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. *Journal of Neuroscience*. 2003;23(34):10756–64
36. Barbeau A, Pourcher E. New data on the genetics of Parkinson's disease. *Canadian Journal of Neurological Sciences*. 1982;9(1):53–60

37. Kurth J, Hubble J, Eggers E, et al., editors. Lack of Association of Cyp2d6 And Mao-B Alleles With Parkinsons-Disease ın A Kansas Cohort. *Neurology*; 1995: Little Brown Co 34 Beacon Street, Boston, MA 02108-1493.
38. Levin J, Kurz A, Arzberger T, et al. The differential diagnosis and treatment of atypical parkinsonism. *Deutsches Ärzteblatt International*. 2016;113(5):61
39. Savoiardo M. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging. *Neurological Sciences*. 2003;24:s35–s7
40. Pagano G, Niccolini F, Politis M. Imaging in Parkinson's disease. *Clinical Medicine*. 2016;16(4):371–5
41. Kumar PV, Appavu R. Comparison and Review of DAT Scan, PET Scan, and α-synuclein In Relation to Parkinson's Disease. *Journal of Student Research*. 2022;11(2)
42. Soni R, Mathur K, Shah J. An update on new-age potential biomarkers for Parkinson's disease. *Ageing Research Reviews*. 2024Ageing Research Reviews:102208
43. Lees AJ, Hardy J, Revesz T. Parkinson's disease. *The Lancet*. 2009;373(9680):2055–66
44. Hely MA, Morris JG, Reid WG, et al. Sydney multicenter study of Parkinson's disease: Non-L-dopa–responsive problems dominate at 15 years. *Movement disorders: official journal of the Movement Disorder Society*. 2005;20(2):190–9
45. Kalia LV, Lang AE. Parkinson's disease. *The Lancet*. 2015;386(9996):896–912
46. Lill CM. Genetics of Parkinson's disease. *Molecular and cellular probes*. 2016;30(6):386–96
47. Dorsey ER, Zafar M, Lettenberger SE, et al. Trichloroethylene: An invisible cause of Parkinson's disease? *Journal of Parkinson's Disease*. 2023;13(2):203–18
48. Tanner CM, Goldman SM, Ross GW, et al. The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk. *Alzheimer's & dementia*. 2014;10:S213–S25
49. Jo S, Kim Y-J, Park KW, et al. Association of NO2 and other air pollution exposures with the risk of Parkinson disease. *JAMA neurology*. 2021;78(7):800–8
50. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. *science*. 1997;276(5321):2045–7
51. Gao H-M, Hong J-S. Gene–environment interactions: key to unraveling the mystery of Parkinson's disease. *Progress in neurobiology*. 2011;94(1):1–19
52. Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. *Trends in Genetics*. 2015;31(3):140–9
53. Elbaz A, Clavel J, Rathouz PJ, et al. Professional exposure to pesticides and Parkinson disease. *Annals of neurology*. 2009;66(4):494–504
54. Brouwer M, Koeman T, van den Brandt PA, et al. Occupational exposures and Parkinson's disease mortality in a prospective Dutch cohort. *Occupational and environmental medicine*. 2015;72(6):448–55
55. Ritz B, Lee P-C, Hansen J, et al. Traffic-related air pollution and Parkinson's disease in Denmark: a case–control study. *Environmental health perspectives*. 2016;124(3):351–6
56. Finkelstein MM, Jerrett M. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. *Environmental research*. 2007;104(3):420–32
57. Jenkins A. Epidemiology of parkinsonism in Victoria. *Medical Journal of Australia*. 1966;2(11):496–502
58. den Heijer JM, Cullen VC, Quadri M, et al. A large-scale full GBA1 gene screening in Parkinson's disease in The Netherlands. *Movement Disorders*. 2020;35(9):1667–74
59. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. *Human molecular genetics*. 2009;18(R1):R48–R59
60. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nature genetics*. 2014;46(9):989–93
61. Kiely AP, Asi YT, Kara E, et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? *Acta neuropathologica*.

2013;125:753–69
62. Lesage S, Anheim M, Letournel F, et al. G51D α-synuclein mutation causes a novel Parkinsonian–pyramidal syndrome. *Annals of neurology*. 2013;73(4):459–71
63. Singleton A, Farrer M, Johnson J, et al. α-Synuclein locus triplication causes Parkinson's disease. *science*. 2003;302(5646):841–
64. Chartier-Harlin M-C, Kachergus J, Roumier C, et al. α-synuclein locus duplication as a cause of familial Parkinson's disease. *The Lancet*. 2004;364(9440):1167–9
65. Ibanez P, Bonnet A, Debarges B, et al. Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease. *The Lancet*. 2004;364(9440):1169–71
66. Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. *Nature Reviews Neuroscience*. 2016;17(4):251–60
67. Brettschneider J, Tredici KD, Lee VM-Y, et al. Spreading of pathology in neurodegenerative diseases: a focus on human studies. *Nature Reviews Neuroscience*. 2015;16(2):109–20
68. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *The Lancet Neurology*. 2008;7(7):583–90
69. Webber PJ, West AB. LRRK2 in Parkinson's disease: function in cells and neurodegeneration. *The FEBS journal*. 2009;276(22):6436–44
70. Zimprich A, Benet-Pagès A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. *The American Journal of Human Genetics*. 2011;89(1):168–75
71. Vilariño-Güell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. *The American Journal of Human Genetics*. 2011;89(1):162–7
72. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. *Nature Reviews Neurology*. 2013;9(8):445–54
73. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *nature*. 1998;392(6676):605–8
74. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science*. 2004;304(5674):1158–60
75. Bonifati V, Rizzu P, Van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science*. 2003;299(5604):256–9
76. Kilarski LL, Pearson JP, Newsway V, et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. *Movement Disorders*. 2012;27(12):1522–9
77. Lill CM, Mashychev A, Hartmann C, et al. Launching the movement disorders society genetic mutation database (MDSGene). *Movement disorders: official journal of the Movement Disorder Society*. 2016;31(5):607–9
78. Edvardson S, Cinnamon Y, Ta-Shma A, et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. *PloS one*. 2012;7(5):e36458
79. Olgiati S, Quadri M, Fang M, et al. DNAJC6 mutations associated with early-onset Parkinson's.
80. Elsayed L, Drouet V, Usenko T, et al. A novel nonsense mutation in DNAJC6 expands the phenotype of autosomal-recessive juvenile-onset Parkinson's disease. *Ann Neurol*. 2016;79(2):335–7
81. Eisenberg E, Greene LE. Multiple roles of auxilin and hsc70 in clathrin-mediated endocytosis. *Traffic*. 2007;8(6):640–6
82. Kalinderi K, Bostantjopoulou S, Fidani L. The genetic background of Parkinson's disease: current progress and future prospects. *Acta Neurologica Scandinavica*. 2016;134(5):314–26
83. Klein C, Westenberger A. Genetics of Parkinson's disease. *Cold Spring Harbor perspectives in medicine*. 2012;2(1):a008888
84. Klein C, Schlossmacher MG. The genetics of Parkinson disease: implications for neurological care. *Nature clinical practice Neurology*. 2006;2(3):136–46

85. Harbo HF, Finsterer J, Baets J, et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. *European Journal of Neurology*. 2009;16(7):777–85
86. MacLeod DA, Rhinn H, Kuwahara T, et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. *Neuron*. 2013;77(3):425–39
87. Berardelli A, Wenning G, Antonini A, et al. EFNS/MDS-ES recommendations for the diagnosis of P arkinson's disease. *European journal of neurology*. 2013;20(1):16–34
88. Lindahl M, Saarma M, Lindholm P. Unconventional neurotrophic factors CDNF and MANF: structure, physiological functions and therapeutic potential. *Neurobiology of disease*. 2017;97:90–102
89. Lee WY, Lee EA, Jeon MY, et al. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3, 4-dihydroxyphenylalanine administration. *Experimental neurology*. 2006;197(1):215–24
90. Axelsen TM, Woldbye DP. Gene therapy for Parkinson's disease, an update. *Journal of Parkinson's disease*. 2018;8(2):195–215
91. Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. *The Lancet*. 2014;383(9923):1138–46
92. Collier TJ, Sortwell CE. Therapeutic potential of nerve growth factors in Parkinson's disease. *Drugs & aging*. 1999;14:261–87
93. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. *Nature Reviews Neuroscience*. 2002;3(5):383–94
94. Behl T, Kaur I, Kumar A, et al. Gene therapy in the management of Parkinson's disease: potential of GDNF as a promising therapeutic strategy. *Current Gene Therapy*. 2020;20(3):207–22
95. Yang W, Tu Z, Sun Q, et al. CRISPR/Cas9: implications for modeling and therapy of neurodegenerative diseases. *Frontiers in molecular neuroscience*. 2016;9:30
96. During M, Samulski R, Elsworth J, et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. *Gene Therapy*. 1998;5(6):820–7
97. Sanders TH, Jaeger D. Optogenetic stimulation of cortico-subthalamic projections is sufficient to ameliorate bradykinesia in 6-ohda lesioned mice. *Neurobiology of disease*. 2016;95:225–37
98. Gradinaru V, Mogri M, Thompson KR, et al. Optical deconstruction of parkinsonian neural circuitry. *science*. 2009;324(5925):354–9
99. Yoon HH, Park JH, Kim YH, et al. Optogenetic inactivation of the subthalamic nucleus improves forelimb akinesia in a rat model of Parkinson disease. *Neurosurgery*. 2014;74(5):533–41
100. Yoon HH, Min J, Hwang E, et al. Optogenetic inhibition of the subthalamic nucleus reduces levodopa-induced dyskinesias in a rat model of Parkinson's disease. *Stereotactic and Functional Neurosurgery*. 2016;94(1):41–53
101. Kravitz AV, Freeze BS, Parker PR, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. *Nature*. 2010;466(7306):622–6
102. Freeze BS, Kravitz AV, Hammack N, et al. Control of basal ganglia output by direct and indirect pathway projection neurons. *Journal of Neuroscience*. 2013;33(47):18531–9
103. Moon HC, Won SY, Kim EG, et al. Effect of optogenetic modulation on entopeduncular input affects thalamic discharge and behavior in an AAV2-α-synuclein-induced hemiparkinson rat model. *Neuroscience letters*. 2018;662:129–35
104. Chuong AS, Miri ML, Busskamp V, et al. Noninvasive optical inhibition with a red-shifted microbial rhodopsin. *Nature neuroscience*. 2014;17(8):1123–9
105. Conklin BR, Hsiao EC, Claeysen S, et al. Engineering GPCR signaling pathways with RASSLs. *Nature methods*. 2008;5(8):673–8

106. Roth BL. DREADDs for neuroscientists. *Neuron*. 2016;89(4):683–94
107. Pienaar IS, Gartside SE, Sharma P, et al. Pharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinson's disease. *Molecular neurodegeneration*. 2015;10:1–22
108. Singh V, Braddick D, Dhar PK. Exploring the potential of genome editing CRISPR-Cas9 technology. *Gene*. 2017;599:1–18
109. Ledford H. CRISPR, the disruptor. *Nature*. 2015;522(7554)
110. Cyranoski D. Chinese scientists to pioneer first human CRISPR trial. *Nature*. 2016;535(7613):476–7